Transcend Medical (Menlo Park, CA) a clinical-stage medical device company focused on the treatment of glaucoma, closed a $16 Series B, bringing the total round to $51M. Participants include Investor Growth Capital, Canaan Partners, Finistere Ventures, HLM Venture Partners, Kaiser Permanente Ventures, Latterell Venture Partners, Morgenthaler Ventures, Split Rock Partners and Technology Partners.
Thanx for your [...]

Elevation Pharmaceuticals (San Diego, CA) a clinical-stage biopharmaceutical company focused on aerosol therapies for respiratory disease and COPD, closed a $17M Series A financing. Participants include Canaan Partners, Care Capital, TPG Biotech and Mesa Verde Venture Partners.

Theraclone Sciences (Seattle, WA) a preclinical-stage biopharmaceutical company focused on monoclonal antibodies for infectious disease and inflammation, closed a $10.6M Series B, bringing the total round to $41M. Participants include Arch Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.

Civitas Therapeutics (Chelsea, MA) a preclinical-stage dry powder pulmonary delivery platform and device combination company focused on for Parkinson’s disease, closed a $20M Series A financing. Participants include Longitude Capital and Canaan Partners.

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

DICOM Grid (Phoenix, AZ) a development-stage bioinformatics company focused on the development of medical imaging software, closed a $7.5M Series A financing. Participants include Canaan Partners and CHL Medical Partners.

Helix Therapeutics (New Haven, CT) a preclinical-stage company developing triplex-forming oligonucleotides to target genome modification with a focused on hemoglobin, immune and lysosomal storage disorders, closed a $2.5M Series A financing. Participants include Canaan Partners and Connecticut Innovations.

Tobira Therapeutics (Manalapan, NJ) a clinical-stage biopharmaceutical company focused on antivirals for HIV and inflammation, closed a $31M B financing. Participants include Novo Ventures, Domain Associates, Frazier Healthcare Ventures, Montreux Equity Partners and Canaan Partners.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland [...]

ReVision Optics (Lake Forest, CA) a clinical-stage medical device company focused on a corneal inlay for presbyopia, closed a $35M Series D financing. Participants include ProQuest Investments, Domain Associates, Canaan Partners and InterWest Partners.

Liquidia Technologies (Research Triangle Park, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $5M Series C financing, bringing the total round to $25M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside, Firelake Capital and PPD

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $13M Series C financing, bringing the total round to $20M. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates, Morningside and Firelake Capital.

Elevation Pharmaceuticals (San Diego, CA) a preclinical-stage biopharmaceutical company focused on developing improved inhaled drug therapies for COPD , closed a $30M Series A financing. Participants include Canaan Partners, TPG Growth, Care Capital and Mesa Verde Venture Partners.